Evaluating the Old and the New in Alzheimer’s Disease: Today’s Options for Improving Diagnosis and Treatment
Released On
December 11, 2024
Expires On
December 31, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Neurology, Primary Care, Psychiatry
Topics
Alzheimer's
This activity is supported by an educational grant from Eisai Inc.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of Neurologists, psychiatrists, primary care physicians, NPs, PAs, and other clinicians involved in the management of patients with Alzheimer’s disease.
Program Overview
This program brings together leading experts to explore advancements in the diagnosis and treatment of Alzheimer’s disease (AD). Presented by Marc E. Agronin, MD, R. Scott Turner, PhD, MD, and Susan Scanland, MSN, this program addresses key challenges and solutions in AD care. Topics include strategies for early detection and diagnosis through cognitive assessments, neuroimaging, and biomarker analysis; the role of novel and investigational disease-modifying therapies and the integration of therapeutic approaches, including FDA-approved treatments and nonpharmacologic interventions. The session emphasizes the importance of multidisciplinary management and shared decision-making with patients and caregivers to create comprehensive and effective care plans.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify biomarkers in screening for Alzheimer’s disease and in continual assessment of symptoms
- Recognize the safety and efficacy of novel therapies that are approved as well as investigational therapies in late-stage development in Alzheimer’s disease
- Assess opportunities to screen for early-stage Alzheimer’s disease including various administration methods, cognitive assessments and imaging
Faculty
Marc E. Agronin, MD
Chief Medical Officer
Frank C. and Lynn Scaduto MIND Institute
Miami Jewish Health
Miami, Florida
Susan Scanland, MSN, CRNP, GNP-BC, CDP
CEO and Founder
Dementia Connection LLC
Clarks Summit, Pennsylvania
R. Scott Turner, PhD, MD, FANA, FAAN
Professor, Department of Neurology
Director, Memory Disorders Program
Georgetown University
Washington, DC
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
Disclosures of Conflicts of Interest
The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:
Dr. Agronin has received consulting fees from Eli Lilly; grant/research support from Biogen, Eisai, Eli Lilly, BMS, Karuna, Alzheon, Cassava, and Suven; honoraria for speaking/teaching from Otsuka; and advisory board fees from Corium.
Dr. Turner has received consulting fees from Re:Cognition Health; and honoraria for speaking/teaching from Eli Lilly.
Ms. Scanland is a stock/shareholder of Dementia Connection, has received consulting fees from Axsome, BioXcel, Eisai, Genentech, Otsuka, and Lundbeck; has received honoraria for speaking/teaching from Teva and Acadia, and advisory board fees from Otsuka, Lundbeck and Acadia.
None of the other faculty, planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions please contact: [email protected] .